History
Parkinson disease began to take a distinct medical form in 1817, when the British physician James Parkinson recorded his observations under the name "Shaking Palsy." Because there was no brain imaging or blood testing as there is today, the disease was described by observing gait, posture, and hand tremor on the street. Later, in the late 19th century, the French neurologist Jean-Martin Charcot established that "the core of Parkinson disease is not only tremor but also slowness and stiffness," making the clinical criteria clear, and the disease name became fixed after Parkinson.
In the early 20th century, it became known that when the brain was observed under a microscope, unusual protein clumps could be seen inside nerve cells, and these came to be called Lewy bodies. In the mid-20th century, the mechanism was revealed by which the dopamine-producing nerve cells in the substantia nigra of the brain decrease, causing the circuits that control movement to break down. This discovery not only explained "why movement slows and the body stiffens," but was also a turning point that set the direction of treatment toward dopamine replacement.
With the introduction of levodopa therapy in the late 1960s, the treatment of Parkinson disease took a leap forward. Whereas previous treatments often only slightly relieved symptoms, levodopa noticeably improved motor function and greatly helped people maintain daily life. As drug therapy later advanced, the problems of long-term treatment, such as "wearing off of the drug effect (off)" and "unwanted movements (dyskinesia)," also came to light, and drug combinations and dosing strategies to address them were developed. In the 1990s, deep brain stimulation (DBS) became widely performed and an important option for controlling tremor and motor fluctuations that are difficult to control with medication.
Recently, the view has been emphasized that Parkinson disease is not only a movement disorder centered on "hand tremor," but may be a systemic disease in which nonmotor symptoms such as changes in sleep, smell, constipation, mood, and cognition can appear years earlier. In recent studies, the connection between the gut and the brain (the gut-brain axis), exposure to environmental toxic substances, and the hypothesis that misfolded proteins spread are being discussed together, and research to detect the disease at an early stage and find treatments that slow its progression has become active.
Causes
In most cases of Parkinson disease, there is no single cause that can be definitively stated as "it is caused by this." It is generally understood that genetic and environmental factors act together so that brain nerve cells are gradually damaged over a long period. The core change is a decrease in the dopamine-producing nerve cells of the substantia nigra, a region deep in the brainstem. Because dopamine is an important signal for initiating movement and carrying it on smoothly, when dopamine becomes deficient, movements can slow (bradykinesia), the body can become stiff (rigidity), and balance can become unsteady.
When explaining the cause, the expression "factors that raise the risk" is more accurate. For example, there are reports that exposure to toxic substances such as certain pesticides, organic solvents, and air pollution, and repeated head trauma, can raise the risk. However, not everyone who has had such exposures develops Parkinson disease; the intensity and duration of exposure, individual genetic vulnerability, age, and overall health status all have an influence together. Conversely, observations are often mentioned that factors such as regular physical activity, a dietary pattern centered on vegetables, fruits, whole grains, and fish, and coffee consumption may lower the risk.
In addition, Parkinson disease may not begin only in the brain. It has been suggested that in some people changes may begin first in the periphery of the body, such as the olfactory nerves or the enteric nervous system, and spread to the brain over time. Recent studies consider that different starting points, "body-first" and "brain-first," may coexist, and that this may cause differences in the combination of symptoms and the rate of progression.
Genetic Epidemiology
A considerable proportion of patients with Parkinson disease have the "sporadic" form without a clear family history, but it is difficult to say that heredity is irrelevant. Patterns related to heredity can be broadly divided into two types. The first is "monogenic Parkinson disease," in which a specific gene variant causes the disease relatively directly. Such cases account for only a portion of the total, but they can be suspected more when onset occurs at a young age or when several members of a family have a similar disease. The second is "complex inheritance," in which multiple genetic variants each raise the risk to a small degree and, with environmental factors added, lead to onset.
Well-known examples include the gene related to alpha-synuclein (SNCA), LRRK2, and parkin (PRKN). In addition, the gene related to glucocerebrosidase (GBA1) has been reported to be associated with the risk of cognitive decline in some patients, suggesting that the course can vary even within the same Parkinson disease. Recent studies conclude that "clear monogenic forms" account for only part of the total, but that common genetic variants can accumulate to create an individual's overall vulnerability.
The most important message from genetic epidemiology is that "having a gene variant does not mean the disease will necessarily develop." Even among family members with the same variant, whether the disease develops, the age of onset, the composition of motor and nonmotor symptoms, and the rate of progression can differ. Genetic testing is therefore often used, in cases of early onset or a strong family history, as supplementary information that aids differential diagnosis, estimates prognosis, or informs decisions about participating in research. For the general public, it is realistic to explain that "a family history may be a warning sign, but that does not mean it is predetermined like fate."
General Epidemiology
Parkinson disease is a progressive neurodegenerative disease that becomes more common with age. In many cases symptoms begin after age 60, but early-onset disease beginning before age 50 also exists. As the elderly population grows worldwide, the number of patients is increasing, and many statistics mention it as "one of the fastest-growing neurological diseases." Many reports show that men are diagnosed more often than women, but there are differences depending on region, race, and access to medical care.
The increasing trend may not be fully explained by increased life expectancy alone. In recent studies, the possibility is discussed that environmental changes such as industrialization, urbanization, and air pollution, occupational exposures, and changes in lifestyle may partly contribute. In addition, there are reports that diagnoses are observed more frequently in agricultural areas and certain industrial areas, strengthening the tendency to consider environmental factors as well.
Parkinson disease is accompanied over a long period not only by motor symptoms but also by nonmotor symptoms, which can increase the burden of treatment and care. Sleep problems, constipation, orthostatic dizziness, depression and anxiety, cognitive decline, and others are often not resolved by medication adjustment alone, so multidisciplinary management is needed. Long-term social and economic burdens can arise not only for patients themselves but also for families (caregivers), and the individual course varies greatly.
Pathogenesis
The pathogenesis of Parkinson disease is too complex to explain with the single phrase "dopamine deficiency," but for the general public, explaining it around its core axes helps understanding. The most central change is that the dopamine nerve cells of the substantia nigra gradually decrease, and as a result the basal ganglia circuits that control movement lose their balance. Because of this, movements slow (bradykinesia), muscles become stiff (rigidity), and tremor or balance problems can appear.
Another feature is the change in which a protein called alpha-synuclein abnormally clumps and accumulates inside nerve cells (Lewy bodies and others). It is discussed that these protein clumps make it difficult for nerve cells to function properly and can trigger inflammatory responses or interfere with the cell's cleaning functions. Some hypotheses also present the view that misfolded alpha-synuclein spreads to neighboring nerve cells as the disease progresses.
At the cellular level, several problems can become intertwined at the same time and create a vicious cycle. When mitochondrial function declines, energy becomes insufficient and oxidative stress increases. At the same time, when the system that processes waste inside the cell (lysosomes and autophagy) weakens, protein debris can accumulate more easily. On top of this, if the brain's immune cells become excessively activated (inflammatory response), nerve cell damage can progress further. Recent studies also discuss the explanation that early changes may begin through the gut-brain axis and the olfactory pathway.
Symptoms
The symptoms of Parkinson disease can be divided into motor symptoms and nonmotor symptoms. Motor symptoms usually begin gradually and progress slowly. Representative examples are rest tremor beginning in one hand or leg, bradykinesia in which movements become slow and smaller, and rigidity in which the body becomes stiff. The way of walking can change so that steps become shorter, the feet drag on the floor, the body leans forward, and turning becomes slow. As the disease progresses, balance can decline and the risk of falling can increase.
Nonmotor symptoms greatly affect patients' quality of life and sometimes appear before motor symptoms. Common examples are reduced sense of smell, constipation, orthostatic dizziness (orthostatic hypotension), sleep problems (especially REM sleep behavior disorder, in which people act out their dreams as if they were real), depression and anxiety, apathy (lack of motivation), fatigue, pain, and urinary disorders. In some people, changes such as "I can't smell things well these days," "I've had constipation for years," or "I shout and flail my arms and legs while sleeping" may appear first.
When the disease has lasted a long time, cognitive function (concentration, planning, processing speed) may decline, or psychiatric symptoms such as visual hallucinations and delusions may appear. If a swallowing disorder develops, food or saliva can pass into the airway and the risk of aspiration pneumonia can increase, and the voice may become softer or articulation less precise, making communication difficult. However, because the combination of symptoms and the rate of progression vary greatly between individuals, it is important to advise people not to conclude that they have Parkinson disease on the basis of a single symptom.
Signs
Signs are the findings objectively confirmed on examination. The most important sign in diagnosing Parkinson disease is bradykinesia. This is not simply "being slow"; it has the characteristic that when repetitive movements are performed, the size and speed of the movements gradually decrease. For example, when tasks such as finger tapping, hand pronation-supination, or toe and heel tapping can be done at first but become progressively smaller and slower, bradykinesia is suspected.
Tremor is usually prominent at rest, and rest tremor that decreases with movement is common. Rigidity appears as a mechanically stiff resistance felt when the doctor passively moves the arms and legs, and cogwheel rigidity, which feels like gear teeth catching, may also be observed. When the gait is observed, arm swing may be reduced, steps shortened, the body bent forward, and turning carried out in several separate steps.
In addition, findings such as reduced facial expression giving an expressionless appearance, a softer voice, and handwriting that becomes progressively smaller are also characteristic. On tests of postural reflexes (such as the pull test), if the response is slow or the person takes several steps backward when pulled back, postural instability is suspected. However, because postural instability often becomes evident at a relatively advanced stage, the combination of bradykinesia, rigidity, and tremor is evaluated with more emphasis in the early stage.
Screening
There is not yet a reliable screening test that "detects Parkinson disease with a single test" in the general population. Instead, methods that combine symptom questionnaires, a simple neurological examination, and some ancillary tests to identify people who appear to be at high risk are being used in clinical practice or studied.
Realistically, clues that help with screening include the following. Tremor or slowness of movement in one hand gradually progresses. Being told that one's handwriting has become smaller or facial expression has decreased. Steps becoming shorter and the feet dragging. Falls becoming more frequent in daily life. If nonmotor symptoms such as reduced sense of smell, constipation, and REM sleep behavior disorder persist for a long time in addition, it is safer to recommend a neurological evaluation rather than regarding them as simple aging.
Recent studies have reported that people with REM sleep behavior disorder may be a group at high risk of later progressing to parkinsonism, emphasizing the importance of checking the sleep history. In addition, smell tests, digital screening tools that track hand movements and gait with smartphones and wearables, and voice analysis are also being studied. These methods are tools that "raise the likelihood" and cannot replace a definitive diagnosis. The purpose of the screening stage lies in "not missing people who are suspected and connecting them to specialist evaluation."
Diagnosis
The basis of diagnosing Parkinson disease is history-taking and neurological examination. First, it is confirmed whether parkinsonism is present, and its centerpiece is bradykinesia. When bradykinesia is confirmed and tremor or rigidity is also present, the likelihood of parkinsonism increases. Next, other causes that can produce parkinsonism are differentiated. For example, the process of distinguishing drug-induced parkinsonism from medications such as antipsychotics, cerebrovascular causes, normal pressure hydrocephalus, and atypical parkinsonism (Parkinson-plus syndromes and others) is important.
The response to levodopa can be a clue supporting the diagnosis. In many patients, motor symptoms improve markedly, but this is not always clear from the beginning, and in atypical parkinsonism the response may be weak or short-lived. Therefore, rather than drawing a conclusion based only on whether there "is or is not" a response, the clinical picture as a whole is interpreted together.
Ancillary tests are performed when needed. Brain MRI is useful for excluding structural lesions or cerebrovascular causes. Dopamine transporter single-photon emission computed tomography (DAT-SPECT) indirectly shows the loss of dopamine neurons and can help differentiate it from other causes of tremor. In recent studies, attempts to improve the accuracy of early diagnosis using alpha-synuclein seed amplification assays in body fluids (such as cerebrospinal fluid) have been reported.
Treatment
The goals of treatment are relieving symptoms, maintaining function, preventing complications, and improving quality of life. Because no treatment has yet been established that reliably stops or reverses the disease itself, the basic approach is to combine medication, rehabilitation, surgery, and lifestyle management to help people "live well." The center of drug therapy is supplementing dopamine function. Levodopa is widely used as the most effective drug, but with long-term use, off time, in which the drug effect wears off quickly, and dyskinesia can develop.
In such cases, strategies of adjusting the dosing interval and dose or adding other drugs are used. For example, dopamine agonists, monoamine oxidase-B inhibitors (MAO-B), and catechol-O-methyltransferase inhibitors (COMT) are used depending on the situation. The choice of drug can vary according to age, occupation, cognitive status, risk of side effects, and lifestyle pattern. Rehabilitation is also very important. Gait, balance, strength, and flexibility training help prevent falls and maintain function. Speech and swallowing therapy is important for communication and for reducing the risk of aspiration, and occupational therapy helps people perform activities of daily living more safely and efficiently.
The representative surgical treatment is deep brain stimulation (DBS), which may be considered when tremor or motor fluctuations that are difficult to control with medication, or drug side effects, greatly reduce quality of life. Treatments such as high-intensity focused ultrasound (HIFU) are also discussed for some symptoms. In recent studies, evidence continues to accumulate that regular exercise benefits motor symptoms, nonmotor symptoms, and quality of life.
Prognosis
Parkinson disease generally progresses gradually over several years, but the rate and pattern of progression vary greatly between individuals. Some people show a relatively mild, tremor-dominant course and maintain function for a long time, while in others gait and balance problems, autonomic symptoms, and cognitive decline may become prominent more quickly. Therefore, when discussing the prognosis, the overall direction of "gradual progression" should be stated while also conveying that it can differ from person to person.
Factors that may affect the prognosis include age at onset, the form of the initial symptoms (whether tremor-dominant or with prominent posture and gait problems), initial cognitive function, risk of falls, and comorbidities. Recent studies have also reported observations that the rate of change may be faster in the prodromal phase before motor symptoms, and that there may be a period after starting treatment in which function improves meaningfully.
Common long-term complications include falls and fractures, aspiration pneumonia due to swallowing disorders, and cognitive decline and dementia. In addition, because visual hallucinations, drowsiness, and impulse control problems can appear as drug side effects, it is necessary for patients and families to observe together and consult the medical team. By combining appropriate medication adjustment and rehabilitation, creating a safe environment, nutritional management, and, when needed, palliative care, many patients can live while maintaining function for a long time.
Prevention
At present, there is no single method that reliably prevents Parkinson disease. However, lifestyle factors that help lower the risk or maintain overall brain health are presented relatively consistently. The most widely recommended is regular exercise. Consistent aerobic exercise, strength training, and balance training help overall brain health and fall prevention and are beneficial for maintaining function even when Parkinson disease is already present.
For diet, a dietary pattern centered on vegetables, fruits, whole grains, fish, and olive oil is beneficial for overall health, and in recent studies the possibility is discussed that such a dietary pattern may be related to risk or progression. In addition, sufficient sleep, management of mental health such as depression and anxiety, and maintaining social activity are also important for long-term function. In terms of environmental exposure, it is reasonable to reduce unnecessary exposure to toxic substances such as pesticides, organic solvents, and heavy metals, and to use personal protective equipment in the work environment. Wearing safety equipment to reduce head trauma can also be recommended.
If symptoms that may represent the prodromal phase, such as REM sleep behavior disorder, reduced sense of smell, and constipation, persist, it is helpful to seek consultation early to check risk factors and adjust lifestyle habits. Even if Parkinson disease cannot be completely prevented, maintaining healthy lifestyle habits and responding quickly to warning signs is the most realistic prevention strategy.